Abstract:
Parkinson’s disease is the second most common neurodegenerative disorder. Parkinson’s disease is a heterogenous disorder which means more than one causative agent contributes to the disease onset. Malfunctioned proteostasis, protein accumulates, protein over and under expression are the characteristic features of Parkinson’s pathology. It is notable that body fluid proteomics has the potential to complement histopathology in disease diagnosis. In this research study we utilized proteomic approach to seek out clinically valuable serum biomarkers for PD. Assessment of changes in protein expression and quantification of disease related proteins was performed through techniques such as 2D gel electrophoresis, Elisa, western blot analysis, and dot blot analysis. Moreover, MTS assay performed to analyse cell viability by exposing healthy cells to patient serum and to healthy control serum. The maximum number of samples used in these protocols were 17 samples of PD and AMC each and 4 controls. The findings of this research study indicated increased alpha synuclein levels in PD serum compared to controls. Differential expression analysis of samples supported the above-mentioned outcomes for alpha-synuclein expression in PD serum vs healthy control. Cst3 levels were upregulated in PD serum compared to AMC and control whereas SHBG levels were downregulated in PD serum than in controls. Rab 9 a Ras GTPase protein increased relatively in PD serum, PrP Saf 32 significantly increased in PD samples compared to controls and higher expression of Amyloid Beta A4, 14-3-3 protein was observed in PD serums. Like the other biomarkers of PD these proteins are yet non-specific but can be potential indicators for PD diagnosis. It is envisioned that further advance in proteomic analyses will provide better opportunities for the diagnosis of PD.
